Open Nav

Opsidio, LLC

  • Martin Philips, Opsidio

Series A lead investor

  • Date:Wednesday, October 17
  • Time:10:30 AM - 10:45 AM
  • Room:Elizabethan B
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Opsidio is developing OpSCF, a monoclonal antibody with a novel target that effectively treats the chronic inflammation that leads to fibrosis. OpSCF is highly effective in 5 independent animal models of fibrosis and remodeling. The first clinical indication will be glomerulonephritis, a subset of CKD, for which there is no effective therapy. OpSCF also shows promise in diabetic and hypertensive kidney disease, which affect millions of patients. OpSCF improves survival in an animal model of renal fibrosis. OpSCF normalizes profibrotic cytokine levels, decreases fibrosis and returns activated myofibroblasts to a quiescent state. OpSCF is highly specific for its target as demonstrated by a high-dose, non-GLP toxicology study that showed no adverse events. OpSCF is humanized, and ready for GMP manufacturing and IND-enabling studies. We are seeking Series A funding, and are 15 months from IND.
  • Company Website:www.opsidio.com
  • Company HQ City:Bryn Mawr
  • Company HQ Country:United States
  • Company HQ State:Pennsylvania           
  • CEO/Top Company Official:Martin Phillips
  • Year Founded:2013
  • Main Therapeutic Focus:Inflammation
  • Lead Product in Development :OpSCF
  • Development Phase of Primary Product:Pre-Clinical
  • Additional Information/Comments:Fibrosis is the result of chronic inflammation. Chronic inflammation is driven by Stem Cell Factor (SCF) expressed on myofibroblasts and other structural cells in disease states. The immune cells that produce chronic inflammatory cytokines share a dependency on the activation of the c-kit receptor. SCF is the exclusive ligand for c-kit. SCF has two isoforms. OpSCF is directed against the isoform of SCF that is expressed only in chronic inflammation. By interrupting the positive feedback loop of cytokine expression, OpSCF returns the pro-fibrotic milieu of chronic inflammation back towards a normal, quiescent state and allowing normal tissue repair to take place.
  • Previous and Current Investors:BioAdvance, private investors
  • Size of Last Investment Round:$1.2 million
  • Total Amount Raised to Date, In All Rounds:$2 million
Speakers
Martin Philips
Opsidio
Back